Precision medicine is often equated with high-tech, exquisitely targeted, million-dollar drug treatments. But at Precision Medicine 2018, hosted by Harvard Medical School’s Department of Biomedical Informatics (DBMI) this week, many of the speakers and panelists were more concerned about improving health for everyone and making better use of what we already have: data.
This is the third year that Jacob Works has made the trip down to Boston Children’s Hospital from Maine. With research assistant Haley Medeiros, he looks at pictures, answers questions, manipulates blocks and mimes actions like knocking on a door. His father, Travis, and another research assistant look on through a window.
“At first, we had to practically bribe him with an iPad with every task,” Travis says. “This year he’s more excited, because he understands more and is more confident and able to share more.”
Jacob, 11, was diagnosed in 2011 with Phelan-McDermid Syndrome, a rare genetic condition that typically causes children to be born “floppy,” with low muscle tone, and to have little or no speech, developmental delay and, often, autism-like behaviors. At the time, Jacob was one of about 800 known cases. But through chromosomal microarray testing, introduced in just the past decade for children with autism symptoms, more cases are being picked up. …
Big data and artificial intelligence are reshaping our world. Earlier this month, at Computefest 2018, organized by the Institute for Applied Computational Science at Harvard University, held the symposium, “The Digital Doctor: Health Care in an Age of AI and Big Data.” Speakers were:
- Finale Doshi-Velez, PhD, Assistant Professor of Computer Science, Harvard University
- Matt Might, Director, Hugh Kaul Personalized Medicine Institute, University of Alabama at Birmingham
- John Brownstein, PhD, Chief Innovation Officer and Director, Computational Epidemiology Lab, Boston Children’s Hospital
- Marzyeh Ghassemi, PhD, Visiting Researcher, Google’s Verily; Postdoctoral Fellow, Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology
- Jennifer Chayes, Managing Director, Microsoft Research New England and New York City
- Emery Brown, PhD, Professor of Medical Engineering and Computational Neuroscience, Massachusetts Institute of Technology
Here are Vector’s five takeaways from the symposium: …
Want to hack something in medicine? Vendors are increasingly eager to contribute their tools to problem-solving teams, like those who will gather November 14 for Boston Children’s Hospital’s Hacking Pediatrics. Seeing an array of tools presented at a showcase at Boston Children’s last week, I felt excited about the possibilities ahead.
Here are a few tools that can help innovators improve health care for patients, caregivers and providers. …
When you go into Netflix to choose a movie or Amazon to buy a book, they’re ready with proactive suggestions for your next purchase, based on your past history. Isaac Kohane, MD, PhD, would like to see something similar happening in medicine, where today, patients often find themselves repeating their medical history “again and again to every provider,” as Kohane recently told Harvard Medicine.
“Medicine as a whole is a knowledge-processing business that increasingly is taking large amounts of data and then, in theory, bringing that information to the point of care so that doctor and patient have a maximally informed visit,” says Kohane, chair of informatics at Boston Children’s Hospital and co-director of the Center for Biomedical Informatics at Harvard Medical School. …
To kick off the final panel of the Global Pediatric Innovation Summit + Awards 2014, moderator Paul Solman (above), business and economics correspondent for PBS Newshour, launched straight into the question: What are we in healthcare doing with big data, and what should we be doing with it?
John Brownstein, PhD, director of Boston Children’s Hospital’s Computational Epidemiology Group and co-founder of HealthMap, said big data has had a significant positive effect on his group’s work. By incorporating social media into their data sets, he noted, they have been able to draw conclusions about large-scale infectious diseases in a matter of weeks.
Sachin Jain, MD, MBA, chief medical Information and innovation officer at Merck, took the role of devil’s advocate, making contrarian points about the “big data revolution.” “We’re not doing enough small data,” he said. “Everyone’s talking about predictive analytics, but they’re not doing basic analytics at the point of care.”
Where is the next generation of therapeutic innovations going to come from? Population-level genomic studies? The fitness trackers on everyone’s wrist? Mining electronic medical records? People’s tweets, Yelps and Facebook posts?
How about all of the above?
What all of these things have in common is data. Lots of it. Some of it represents kinds of data that didn’t exist 5 or 10 years ago, but all of it is slowly beginning to fuel the pharma sector’s efforts to create the next blockbuster drug or targeted therapeutic.
At least, it should be. …
Ed. note: This is the second in a two-part series on making clinical trial data more transparent. Click here for part 1.
To grossly oversimplify, there are two kinds of people in the world: those who want to see data from clinical trials made widely and freely available, and those who would rather have the data restricted for privacy or business reasons. And as we noted in our last post, there are valid arguments to be made on both sides.
But is there a way to balance the benefits of openness and the safety of confidentiality? …
Ed. note: This is the first in a two- part series on making clinical trial data more transparent. Click here for part 2.
2013 was the year when big data became, well, big. Everyone from investment companies to public utilities to security agencies—including medical researchers—are now clamoring for as much data on as many subjects and topics as they can get their digital hands on.
But while data in other fields are becoming ever more open, clinical trial data—especially from corporate-sponsored trials—are relatively hard for medical researchers to obtain. …
Do you have a cough?
If you’re sitting at home with a sore throat, your answers to those two questions could be enough to tell whether you should see a doctor for a strep test, thanks to a new risk measure created by Kenneth Mandl, MD, MPH, and Andrew Fine, MD, MPH, at Boston Children’s Hospital.
Called a “home score,” the measure combines the two questions above, your age, and data on the level of strep activity in your geographic area. The basic idea is that your symptoms, plus the big picture of what’s happening in your neighborhood, is a strong enough predictor to for you to go to the doctor for a throat swab.
Thought it’s just a research tool for now, if it were it were packaged into an app and fed the right data (localized strep test results from a health center or medical testing company, for example), the home score could allow someone with a sore throat to make an informed decision about whether they should consider going to the doctor.